Develops protein-based therapeutics, focusing on immuno-oncology and respiratory diseases.
Pieris Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative anticalin-based drugs. These drugs are derived from anticalin proteins, which are therapeutic proteins with low molecular weight originating from lipocalins found naturally in human blood plasma and bodily fluids.
The company's diverse pipeline includes several promising candidates. Among these is PRS-060/AZD1402, currently in Phase II clinical trials, targeting IL-4Ra to address asthma and other inflammatory diseases. Another notable candidate, PRS-220, is an oral inhaled Anticalin protein focusing on connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. Pieris Pharmaceuticals also advances its immune-oncology program with Cinrebafusp alfa, a 4-1BB/HER2 bispecific drug designed for treating both HER2-high and HER2-low expressing gastric cancers.
In addition to its lead candidates, Pieris Pharmaceuticals is developing PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases in Phase 1 clinical trials, alongside PRS-352, a preclinical program addressing undisclosed targets within immuno-oncology. The company maintains strategic collaborations with industry leaders such as Les Laboratoires Servier, AstraZeneca AB, Seagen Inc., and Eli Lilly and Company, among others, underscoring its commitment to advancing therapeutic innovations and expanding treatment options for patients worldwide.